Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Among other segments, the company’s biologic products such as DBMs and synthetic bone grafts have application in general orthopaedic, spine and sports-medicine procedures.
The company raised $7.4MM in its last round of funding, in 2013.
Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Among other segments, the company's biologic products such as DBMs and synthetic bone grafts have application in general orthopaedic, spine and sports-medicine procedures.
Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Among other segments, the company’s biologic products such as DBMs and synthetic bone grafts have application in general orthopaedic, spine and sports-medicine procedures.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
